Multifunctional Bioconjugate for Cancer Cell-Targeted Theranostics.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Targeted cancer imaging and drug delivery are crucial for effective theranostics.
• MUC1, a transmembrane glycoprotein, presents a promising target for cancer-specific therapies.

Purpose of the Study:

• To design and construct a MUC1-targeting hybrid nanoparticle for cancer theranostics.
• To create a multifunctional bioconjugate for targeted drug delivery, imaging, and cytotoxicity assessment.

Main Methods:

• A MUC1-targeting aptamer (APT) was used to create a hybrid nanoparticle (1-NPs-QDs-hAPT, Vehicle).
• The nanoparticle was loaded with doxorubicin (DOX) to form Vehicle-DOX, optimizing drug payload and fluorescence quenching.
• Confocal microscopy and cytotoxicity studies were performed to evaluate MUC1-targeting capabilities.

Main Results:

• The developed Vehicle-DOX demonstrated MUC1-targeted cell uptake and imaging capabilities.
• The bioconjugate enabled tracking of MUC1-targeted drug release.
• Vehicle-DOX exhibited MUC1-targeted cytotoxicity in vitro.

Conclusions:

• The multifunctional Vehicle-DOX bioconjugate shows potential for MUC1-targeted cancer theranostics.
• This approach facilitates precise drug delivery and real-time monitoring of treatment efficacy.
• Further in vivo studies are warranted to validate its therapeutic potential for tumors.